[Analysis of the global burden of soft tissue and extraosseous sarcomas among individuals aged from 15 to 49 based on global burden of disease database].
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Objective: To systematically analyze the disease burden of soft tissue and extraosseous sarcomas (STEOS) among individuals aged 15-49 years old worldwide and in the Chinese mainland from 1990 to 2021, and explore the relationship between socio-economic development and disease burden. Methods: Incidence, mortality and disability-adjusted life year (DALY) for STEOS in populations aged from 15 to 49 were collected from the Global Burden of Disease (GBD2021) database. The temporal trends in disease burden were quantified using the average annual percentage change (AAPC). The socio-demographic index (SDI) was employed to examine the socio-economic development. Results: The global incidence rate of STEOS among individuals aged 15-49 remained relatively stable (AAPC=-0.13, 95%CI:-0.23--0.04, P=0.299). In contrast, significant declines were observed in both mortality rate (AAPC=-0.39, 95%CI:-0.47--0.31, P<0.001) and DALY rate (AAPC=-0.46, 95%CI:-0.54--0.38, P<0.001). In the Chinese mainland, the incidence of STEOS among individuals aged 15-49 remained relatively stable (AAPC=-0.10, 95%CI:-0.31-0.10, P=0.314), while the mortality rate (AAPC=-1.42, 95%CI:-1.59--1.25, P<0.001) and DALY rate (AAPC=-1.62, 95%CI:-1.82--1.42, P<0.001) declined steadily from 1990 to 2021. In 2021, high-SDI regions reported high incidence rate (1.38/100 000, 95%UI:1.28/100 000-1.46/100 000), mortality rate (0.42/100 000, 95%UI:0.39/100 000-0.43/100 000) and DALY rate (23.05/100 000, 95%UI:21.84/100 000-24.00/100 000), while low-SDI regions reported high mortality rate (0.36/100 000, 95%UI:0.27/100 000-0.54/100 000) and DALY rate (20.50/100 000, 95%UI:15.46/100 000-30.96/100 000). Conclusion: The disease burden of STEOS worldwide and in the Chinese mainland populations aged from 15 to 49 has declined consistently. Notably, STEOS constitutes a substantial disease burden, particularly among countries and regions with high-SDI and low-SDI in 2021.